Crossmark

Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

Published Online: 2018-08-04

Published Print: 2018-12

Authors

Qin, Shukui

Kruger, Eliza

Tan, Seng Chuen

Cheng, Shuqun

Wang, Nanya

Liang, Jun
Funding

Funding for this research was provided by:

Sanofi China Investment Company
License Information

Text and Data Mining valid from 2018-08-04
More Information

Article History

Received: 20 March 2018

Accepted: 23 July 2018

First Online: 4 August 2018

Document is current